Biocept Inc represents values of innovation, quality, and commitment to improving patient care. With a corporate philosophy focused on leveraging advanced diagnostics, Biocept aims to enable oncologists to make more informed treatment decisions. By developing and commercializing proprietary liquid biopsy tests, the company helps provide actionable biomarker information for personalized medicine. Biocept embraces cutting-edge technologies, rigorous research practices, and strategic collaborations to deliver reliable and accurate results. Through their dedication to accuracy, speed, and accessibility, Biocept is streamlining the diagnosis and monitoring of cancer, ultimately facilitating better patient outcomes.

Biocept Inc is primarily present in the United States. As a leading molecular diagnostics company, Biocept focuses on providing advanced oncology testing services to physicians and patients nationwide. With their state-of-the-art laboratory facilities and cutting-edge technology, Biocept offers innovative liquid biopsy tests that detect and monitor various cancer biomarkers. By leveraging their expertise in circulating tumor cells and circulating tumor DNA analysis, Biocept aims to enhance cancer detection and treatment strategies, ultimately improving patient outcomes.

Biocept Inc has achieved significant milestones in its history. Some notable achievements of the company include the successful launch of their liquid biopsy platform, which enables the detection and monitoring of cancer through blood samples. They have also secured multiple patents related to their proprietary technology. Biocept Inc has established partnerships with renowned healthcare institutions and laboratories, further expanding their reach and impact. Additionally, the company has announced successful collaborations with pharmaceutical companies to develop precision medicine strategies. These milestones highlight Biocept Inc's commitment to innovation, research, and improving cancer diagnosis and treatment.

Biocept Inc is a leading molecular diagnostics company that specializes in providing liquid biopsy tests for cancer detection and monitoring. The company was founded in 1997 and is headquartered in San Diego, California. Biocept utilizes proprietary technology to analyze circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) present in a patient's blood sample. These tests aid in early cancer detection, treatment selection, and monitoring of therapeutic effectiveness. The company collaborates with healthcare providers, research institutions, and pharmaceutical companies to advance personalized medicine and enhance patient care. Biocept Inc has gained recognition for its innovative solutions and continues to make significant contributions in the field of molecular diagnostics.

The main competitors of Biocept Inc in the market are companies like Guardant Health, Inc. and Genomic Health, Inc. These companies also provide molecular diagnostic testing services and solutions for cancer detection and treatment. However, what sets Biocept apart is its unique liquid biopsy technology and its ability to capture and analyze tumor cells from a simple blood sample. With its innovative and efficient testing methods, Biocept Inc remains at the forefront of the market, offering reliable and accurate diagnostic solutions to patients and healthcare providers.

Biocept Inc is primarily active in the healthcare and biotechnology industries. As a leading molecular diagnostics company, Biocept specializes in providing clinically actionable information to healthcare providers, assisting in the treatment of patients with cancer. Through its proprietary liquid biopsy technology, Biocept enables the detection and monitoring of circulating tumor cells and circulating tumor DNA, aiding in the diagnosis and management of various types of cancer. With its innovative solutions and commitment to advancing personalized medicine, Biocept continues to make significant contributions to the healthcare industry.

Biocept Inc. operates as a molecular diagnostics company. Its business model revolves around developing and commercializing proprietary circulating tumor cell and circulating tumor DNA assays to provide physicians with insights for treating and monitoring cancer patients. By utilizing patented technologies, Biocept's liquid biopsy tests detect and analyze tumor-associated biomarkers from a simple blood sample. This enables healthcare providers to make informed decisions regarding the selection of targeted therapies, monitoring treatment response, and detecting the development of resistance mutations in cancer patients. Biocept aims to improve patient outcomes and contribute to advancing precision medicine in oncology.

Biocept hissesinin F/K oranı -0,00.

Biocept KUV 0,01 dir.

Biocept için AlleAktien Kalite Skoru 5/10'dur.

beklenen Biocept cirosu 6,60 Milyon. USD dir.

beklenen Biocept karı -25,02 Milyon. USD olarak gerçekleşmiştir.

Biocept Inc specializes in the development and marketing of liquid biopsy technologies and products for cancer diagnostics. The company's business model involves generating higher income and increasing profits through the sale of diagnostic tests and services for cancer medicine. Biocept Inc offers a wide range of diagnostic tests for cancer patients aimed at early detection and more accurate classification of the disease. These products range from Helix for breast and lung cancer to Pathnostics for prostate cancer, as well as a variety of tests for rare cancer types. These diagnostic tests use advanced technologies like liquid biopsy to provide patients with precise and comprehensive information about their cancer. The company has developed its technology to be able to isolate cancer cells from a small amount of blood, providing an accurate and non-invasive method for cancer diagnosis that spares patients from undergoing a biopsy. This technology allows doctors to tailor treatment more precisely and monitor the progression of the disease in an accurate manner. In addition to products, Biocept Inc also provides services for cancer patients. The company has a team of experienced medical professionals who perform the diagnostic tests and interpret the results. The results of these tests are an important basis for making decisions about the patient's further treatment. The company's focus is on delivering high-quality diagnosis to ensure the best possible care for each individual patient. In the field of medical diagnostics, Biocept Inc has established a strong competitive position. Through continuous development of its products and services, the company has built a reputation for innovative and reliable diagnostic tests in the market. The company also leverages partnerships with other companies in the healthcare industry to expand its business and introduce new products and services to the market. With its advanced technologies and high standardization measures, Biocept Inc is well positioned for collaboration with other companies. These partnerships enable faster product launches and better integration of the partners' products and services. Overall, Biocept Inc's business model is focused on generating higher income and increasing profits through the development and marketing of liquid biopsy technologies and products for cancer diagnostics. The company strives to continuously improve its products and services and introduce new partnerships to thrive in a competitive environment.

Biocept, yılda kez dağıtılmak üzere 0 USD tutarında temettü ödemektedir.

Biocept için şu an için temettü hesaplanamıyor veya şirket temettü dağıtmıyor.

Biocept şirketinin ISIN kodu US09072V5012’dir.

Biocept 'nin WKN'si A2QEQE 'dir.

Biocept için Ticker BIOC’dir.

Son 12 ay içerisinde Biocept, tutarında bir temettü ödedi. Bu, yaklaşık olarak oranında bir temettü verimine denk gelmektedir. Gelecek 12 ay için Biocept, tahmini olarak 0 USD tutarında bir temettü ödemesi yapacak.

Biocept şirketinin mevcut temettü verimi .

Biocept dönemsel olarak temettü ödemesi yapar. Bu ödemeler aylarında gerçekleştirilir.

Biocept, son 0 yıl içerisinde her yıl temettü ödedi.

Önümüzdeki 12 ay için 0 USD tutarında temettü ödenmesi beklenmektedir. Bu, 0 % oranında bir temettü verimidir.

Biocept, 'Sağlık' sektörüne atanmıştır.

Son Biocept tarihinde 0 USD tutarındaki en son temettüyü alabilmek için, hisseyi 06.09.2024 tarihindeki Ex-Tag'den önce portföyünde bulundurman gerekiyordu.

Son ödeme tarihi 06.09.2024 olarak gerçekleşti.

2023 yılında Biocept tarafından 0 USD olarak temettüler dağıtıldı.

Biocept hisselerinin temettüleri USD olarak dağıtılır.